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During the primary response, the commitment of the CD8+ T cell to
Blimp-1 expression and the terminal differentiation that Blimp-1
induces must be timed so as not to impair the process of clonal
expansion. We determined whether the Hippo pathway, which
links cell–cell contact to differentiation in other cell lineages, con-
trols Blimp-1 expression. Activating the CD8+ T cell with antigen
and IL-2 causes expression of the core Hippo pathway compo-
nents, including the pivotal transcriptional cofactor Yap. Contact
between activated CD8+ T cells induces Hippo pathway-mediated
Yap degradation and Blimp-1 expression; a Hippo-resistant, stable
form of Yap suppresses Blimp-1 expression. Cytotoxic T lympho-
cyte antigen 4 (CTLA-4) and CD80 comprise the receptor–ligand
pair that mediates contact-dependent Hippo pathway activation.
In vivo, CD8+ T cells expressing Hippo resistant-Yap or lacking
CTLA-4 have diminished expression of the senescence marker,
KLRG1, during a viral infection. The CTLA-4/Hippo pathway/
Blimp-1 system may couple terminal differentiation of CD8+ T cell
with the magnitude of clonal expansion.
During the ﬁrst week of a viral infection, virus-speciﬁc CD8
+
T cells must coordinate two interdependent but mutually
exclusive processes: rapid replication to generate the precursors
of effector cells and development of effector cells from these
precursors. These two cellular responses must be appropriately
timed, because full effector differentiation, so-called terminal
differentiation, is associated with the diminution or loss of rep-
licative function. If terminal differentiation occurs too early
during the process of clonal expansion, then paradoxically, the
rate at which effector cells would be generated would be in-
sufﬁcient for host defense. The ability of the CD8+ T cell to
suspend terminal differentiation until clonal expansion has oc-
curred is documented by the observation that CD62Llo, CD127lo
CD8+ T cells speciﬁc for Listeria monocytogenes did not appear
until day 4 postinfection (1). Conversely, inappropriate delay of
terminal differentiation would also impair control of an infection.
Recent studies that have focused on identifying the determi-
nants of terminal differentiation of the CD8+ T cell have ad-
vanced our understanding of this developmental step. The
transcriptional repressor, Blimp-1, and the T-box transcription
factors, T-bet (2) and Eomesodermin (Eomes) (3), have been
shown to regulate the differentiation of effector CD8+ T cells.
Absence of Blimp-1 is associated with virus-speciﬁc CD8+ T cells
having impaired cytolytic function, lower expression of the se-
nescence-associated marker killer cell lectin-like receptor G1
(KLRG1), and enhanced development of the central memory
phenotype (4, 5). The acquisition of effector functions [but
maintenance of replicative function in both CD4+ (6) and CD8+
(7) T cells] is consistent with the capacity of Blimp-1–deﬁcient
CD8+ T cells to express IFN-γ and cytolytic activities, although
at suboptimal levels. These loss-of-function studies (4, 5) in-
dicate that Blimp-1 is required for terminal differentiation by the
activated CD8+ T cell, which it for two other lymphocytic line-
ages, the B (8) and NK (9) cells. T-bet promotes Blimp-1 ex-
pression in the natural killer (NK) cell (9), and a similar role may
be expected in the CD8+ cell, because T-bet– (2) and Blimp-1–
deﬁcient (4, 5) CD8+ T cells have similar differentiation phe-
notypes. Moreover, in vitro studies have shown that T-bet ex-
pression enables signaling by the IL-2 receptor to induce Blimp-1
transcription (10). Although T-bet levels are always higher in
terminally differentiated, KLRG1+ cells than at other stages of
differentiation, it may be that the ratio of T-bet and Eomes is
also critical (11). Eomes shares with T-bet a capacity to mediate
the development of effector function (12), but it differs from T-
bet in being necessary for the development of memory CD8+ T
cells having secondary proliferative capability (3) in response to
the mammalian homolog of the target of rapamycin (mTOR)
(13) or T-cell factor (TCF-1) (14) signaling.
The extracellular signals that regulate the expression of these
transcription factors include antigen and the cytokines IL-2, IL-
12, IL-21, and IL-27 (15–19). The inﬂammatory cytokines, IL-
12 and IL-27, are produced by dendritic cells and cells of the
innate immune system that have been stimulated by microbial
products, whereas IL-2 and IL-21 are secreted by antigen-
stimulated CD4+ and CD8+ T cells. Although both types of
cytokines may increase during the course of an infection and
therefore, provide temporal elements by which the CD8+ T cell
could time its commitment to terminal differentiation, these
signals also would be coupled to the extent of microbial repli-
cation, which may not reﬂect the magnitude of clonal expan-
sion. IL-2, acting in a paracrine manner, could meet the re-
quirement of being directly correlated with the number of
antigen-stimulated T cells, but this cytokine has dual functions
in promoting the development of both terminally differentiated
effector cells and replication-competent memory cells (20–24).
Thus, neither inﬂammatory- nor T-cell–derived cytokines are
likely to be the ultimate determinants of Blimp-1 expression and
terminal differentiation.
In multiple cell types of invertebrates and vertebrates, termi-
nal differentiation is directed by a highly conserved develop-
mental system, termed the Hippo pathway. The Hippo pathway
is triggered when replicating cells come into contact with each
other, enabling a receptor–ligand pair to activate a serine/threonine
kinase cascade (25). This activation results in the phosphoryla-
tion and proteosomal degradation of the transcriptional cofac-
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tor, Yap, which permits differentiation to proceed (26). A po-
tential role for the Hippo pathway in regulating the expression
of Blimp-1 and Eomes is suggested by the independent obser-
vations that Blimp-1 and the Hippo pathway, respectively, are
required for the normal differentiation of skin (27, 28) and that
Yap, by interacting with the transcription factor TEA domain
(TEAD), induces Eomes expression in trophoectoderm (29, 30).
Because cell–cell contact triggers the Hippo pathway, the like-
lihood of which would be proportional to the relative frequency
of the interacting cells, this pathway would fulﬁll the hypothetical
requirement of linking the magnitude of clonal expansion by
activated CD8+ T cells to their commitment to terminal differ-
entiation. Accordingly, we have examined the role of the Hippo
pathway in regulating Blimp-1 expression by the CD8+ T cell.
Results
Kinase Cascade of the Hippo Pathway Is Assembled by the Activated
CD8+ T Cell and Regulates the Expression of Blimp-1. Puriﬁed OT-I
cells were incubated with SIINFEKL peptide alone or IL-2 for
24 h and then assessed for expression of the components of the
Hippo pathway. Resting CD8+ T cells expressed only Mst1
protein, although mRNA for WW45, Lats1, and Mob1 was
detected. The presence of WW45, Lats1, and Mob1 protein re-
quired signaling both through the T-cell receptor (TCR) and IL-
2 receptor, indicating IL-2–dependent posttrancriptional regu-
lation of these components. Transcription and translation of
TEAD1 and TEAD3, two transcription factors of the Hippo
pathway, occurred in cells receiving both TCR and IL-2 receptor
signals (Fig. 1).
The expression of Yap was more complex insofar as stimu-
lating OT-I cells with TCR and IL-2 induced the rapid appear-
ance of mRNA but not the protein (Fig. 2 A and B). The
appearance of Yap mRNA after only 15 min TCR stimulation
suggested that it was released from a preformed pool, which was
consistent with actinomycin D having no inhibitory effect (Fig.
2A). We considered whether the absence of Yap protein in an-
tigen and IL-2–stimulated cells could be caused by its degrada-
tion secondary to contact between activated cells. Adding
resting, polyclonal naïve CD8+ T cells to interfere with this
process permitted the detection of Yap in the activated OT-I
cells (Fig. 2C). Yap mRNA in the recovered CD8+ T cells was
not increased by the addition of naïve T cells, suggesting that the
appearance of Yap protein reﬂected its stabilization rather than
increased production (Fig. 2C). To show that the absence of Yap
in contacting activated CD8+ T cells was caused by its phos-
phorylation at serine-382 of the phosphedegron domain, we
transduced activated OT-I cells with hemagglutin (HA) -tagged
WT Yap-HA, Yap S112A-HA, in which the serine mediating
cytoplasmic retention after phosphorylation was mutated to al-
anine, and Yap S382A-HA, respectively. After additional culture
of the transduced cells for 48 h in IL-2, only Yap in which serine-
382 had been substituted with alanine was present (Fig. 2D).
Therefore, as in other cell types, contact between activated
CD8+ T cells triggers the serine–kinase cascade that leads to
phosphorylation and degradation of Yap.
CTLA-4–CD80 Is the Receptor–Ligand Pair Mediating Activation of the
Hippo Pathway. The receptor and its ligand that triggers the
Hippo pathway are expressed by activated but not resting CD8+
T cells (Fig. 2C). Among the membrane proteins induced by
activation of the CD8+ T cell are CD80 and its receptor, CTLA-
Fig. 1. Expression of core components of the Hippo pathway by OT-I cells.
(A) Immunoblot analysis of components of the Hippo pathway in whole-cell
lysates prepared from naïve OT-I cells and OT-I cells stimulated for 24 h with
0.1 nM SIINFEKL peptide alone or with IL-2 (TCR + IL-2). (B) Bar graph
showing the mRNA levels of these components in identically treated samples
of OT-I cells relative to those levels for CD3ε (given an arbitrary level of one).
*P < 0.05; ***P < 0.001. Data presented are the mean ± SEM (n = 3).
Fig. 2. The regulation of Yap expression in OT-I cells. (A) Bar graph showing
the mRNA levels, relative to the levels for CD3ε, for Yap in naive OT-I cells
and OT-I cells stimulated for timed intervals with 0.1 nM SIINFEKL peptide in
the absence or presence of actinomycin D. Data presented are the mean ±
SEM. (B) Immunoblot analysis of Yap in whole-cell lysates prepared from
naïve OT-I cells and OT-I cells stimulated for 24 h with 0.1 nM SIINFEKL
peptide alone (TCR) or together with IL-2 (TCR + IL-2). (C) Levels of Yap
protein (Lower) and Yap mRNA levels (Upper) in whole-cell lysates prepared
from naïve Thy1.2+ OT-I cells and Thy1.2+ OT-I cells that had been stimulated
with SIINFEKL peptide and IL-2 for 24 h alone or in the presence of 10-fold
excess of nonactivated Thy1.1+ C57BL/6 CD8+ T cells. The Thy1.2+ OT-I cells
were recovered by MACS puriﬁcation, and Yap protein and mRNA were
assessed. Data presented are the mean ± SEM. (D) Immunoblot analysis using
antihemagglutin (anti-HA) of whole-cell lysates prepared from retrovirally
transduced OT-I cells that expressed ectopic WT Yap tagged with HA (Yap-
HA) and Yap in which serine 112 had been mutated to alanine (Yap S112A-
HA) or serine-382 had been mutated to alanine (Yap S382A-HA). Lysates
were cultured for 48 h with IL-2. ***P < 0.001.
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4. We assessed the requirements for the expression of the pre-
ferred ligand for CTLA-4, CD80 (31), by culturing OT-I cells
with SIINFEKL peptide alone and combined with IL-2. Al-
though a low level of CD80 transcription and protein was found
in the naïve, resting CD8+ T cell, TCR and IL-2 signaling in-
creased CD80 mRNA by more than 1,000-fold, leading to robust
expression of CD80 protein (Fig. 3 A and B). The other potential
ligand for CTLA-4, CD86, was relatively unaffected by T-cell
activation. The possibility that CD80 and CD86 had a role in
activation of the Hippo pathway was examined by including
blocking antibodies to these proteins in cultures of activated OT-
I CD8+ T cells. Yap protein was shown by immunoblot analysis
in lysates of OT-I cells that had been activated with antigen and
IL-2 in the presence of these blocking antibodies but not lysates
of similarly activated cells in the absence of anti-CD80/86 (Fig.
3C). Blocking CD80/86 did not lead to the appearance of Yap
protein in OT-I cells activated by the TCR alone, indicating that
expression of the protein required both TCR and IL-2 stimula-
tion. The stabilization of Yap protein and inhibition of Hippo
pathway activation by blocking CD80/86 was conﬁrmed by con-
focal analysis of the activated CD8+ cells, in which nuclear Yap
was shown (Fig. 3D). Because all CD80 in these cultures was on
CD8+ T cells, with no contaminating MHC class II-expressing
cells (SI Appendix, Fig. S1A), we conclude that Yap stability was
controlled by interaction between the activated OT-I cells.
CD80 and CD86 have two receptors, CD28 and CTLA-4. We
excluded CD28 from having a role in Hippo pathway activation
by showing that its ligation on activated CD8+ T cells, on which
CD80/86 had been blocked, did not lead to the loss of Yap
protein (SI Appendix, Fig. S1B). We focused, then, on the
requirements for the expression at the plasma membrane of the
other receptor for CD80, CTLA-4. Although ligation of the TCR
on OT-I cells induced a greater than 100-fold increase in CTLA-
4 mRNA, optimal CTLA-4 protein, as assessed by immunoblot
analysis of cell lysates, required the addition of IL-2 (Fig. 4 A and
B). Expression at the plasma membrane of CTLA-4 also is
a regulated event and can be suppressed by the addition of
nonactivated CD8+ T cells (Fig. 4C). The role of soluble factors
secreted by activated CD8+ T cells in regulating plasma mem-
brane expression of CTLA-4 was excluded by the use of transwell
chambers. When noncontacting, activated CD8+ T cells were
separated by a semipermeable membrane from contacting, ac-
tivated CD8+ T cells, the former maintained low plasma mem-
brane expression of CTLA-4, despite the latter having high
expression (Fig. 4D).
Having determined the conditions for optimal expression of
CTLA-4, we could assess whether its speciﬁc ligation by beads
coated with CTLA-4 antibody activated the Hippo pathway in
CD8+ T cells, in which this triggering event was otherwise
blocked by anti-CD80/86 antibodies. Ligation of CTLA-4 by this
means induced serine and threonine phosphorylation of Mst1
and Lats1, respectively (Fig. 5A). To evaluate phosphorylation of
Yap by activated Lats1, we retrovirally introduced the degrada-
tion-resistant Yap S382A mutant into CD8+ T cells. Ligation of
CTLA-4 by the immobilized anti–CTLA-4 induced phosphory-
lation of serine-112 in these cells (Fig. 5B). Ligation of CTLA-4
also caused, in a dose–response manner, the loss of Yap protein,
which was shown both by immunoblot analysis of cell lysates and
confocal analysis of anti-Yap–stained cells (Fig. 5 C and D). The
essential role of CTLA-4 in Hippo pathway activation was con-
ﬁrmed with loss-of-function experiments by the use of CTLA-4−/−
OT-I cells, which had been puriﬁed from healthy, young mice
and thus, had a naïve, CD62Lhi phenotype (SI Appendix, Fig.
S2). Activation of these cells with antigen and IL-2 did not in-
duce the loss of Yap protein, which was observed with WT OT-I
cells (Fig. 5E). The possibility that the inability of CTLA-4−/−
T cells to activate the Hippo pathway may contribute to the
immunopathology associated with this deﬁciency is supported
by the ﬁnding that, in CTLA-4−/− mice, the proliferating CD4+
Fig. 3. The role of CD80/86 in triggering the Hippo pathway during contact between activated CD8+ T cells. (A) Bar graph showing the mRNA levels of CD80
and CD86 relative to the levels of CD3ε in naïve OT-I cells and OT-I cells stimulated for 24 h with 0.1 nM SIINFEKL peptide alone (TCR) or together with IL-2
(TCR + IL-2). Data presented are the mean ± SEM. (B) Naïve and TCR + IL-2–stimulated OT-I cells were also assessed by FACS for membrane expression of CD80
and CD86 (shaded histogram, isotype control; black line, speciﬁc antibody). (C) Immunoblot analysis of Yap in cell lysates prepared from naïve OT-I cells or OT-
I cells that had been stimulated for 24 h with SIINFEKL peptide in the absence or presence IL-2 and the presence of isotype control antibodies or blocking
antibodies to CD80 and CD86. (D) Analysis by confocal microscopy of Yap expression by naïve OT-I cells or OT-I cells that had been stimulated for 24 h with
SIINFEKL peptide and IL-2 in the presence of isotype control antibodies or blocking antibodies to CD80 and CD86 (green, anti-Yap; blue, DAPI). (Scale bars:
50 μm.) ***P < 0.001.
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and CD8+ T cells in lymph nodes showed nuclear Yap protein
(Fig. 5F).
Blocking the Hippo Pathway Suppresses CD8+ T-Cell Differentiation.
We assessed the role of the Hippo pathway on the expression of
two transcription factors that regulate the differentiation of the
CD8+ T cell. Eomes is necessary for the maintenance of the
replicative potential of memory CD8+ T cells in secondary
responses, and Eomes expression is maintained in activated
CTLA-4−/− CD8+ T cells (32). In contrast, Blimp-1 is required
for terminal differentiation and replicative senescence of the
CD8+ T cell (4, 5). The effects of Hippo pathway activation in
other cell types can be prevented by ectopic expression of Yap
5SA, a form of the protein in which the ﬁve serine targets of the
Lats1/2 kinase have been mutated to alanine. Indeed, the sta-
bilization of endogenous Yap in activated CD8+ T cells by
blocking CD80/86 and ectopically introducing Yap 5SA into
CD8+ T cells led to comparable intracellular levels of Yap
protein (SI Appendix, Fig. S3). Therefore, the ﬁnding that ec-
topic Yap 5SA maintained the levels of Eomes protein (Fig. 6A)
and mRNA (SI Appendix, Fig. S4A) in activated CD8+ T cells,
without affecting the levels of T-bet mRNA (SI Appendix, Fig.
S4B), indicates that the Hippo pathway negatively regulates
Eomes, which may impair the replicative potential of the anti-
gen-experienced CD8+ T cell.
We assessed the role of the Hippo pathway in regulating
Blimp-1 by the use of Prdm1gfp/+ CD8+ T cells, in which the
expression of Blimp-1 is reported by the GFP-modiﬁed Prdm1
allele. Ectopically expressing Yap 5SA in these cells repressed
the appearance of GFP+ cells after in vitro activation, which
contrasts the response of activated cells that had been trans-
duced with the control vector that became GFP+ (Fig. 6B). The
capacity of Yap 5SA to suppress Blimp-1 transcription was
conﬁrmed by the demonstration of a fourfold lower level of
Blimp-1 mRNA in activated CD8+ T cells expressing Yap 5SA
than the vector control cells (Fig. 6C).
The capacity of Yap 5SA to maintain Eomes expression and
suppress Blimp-1 expression by CD8+ T cells in vitro predicts
that it may suppress terminal differentiation of the activated
CD8+ T cell in vivo. To assess this prediction, we infected mice
with a modiﬁed form of murine γ-herpesvirus-68 that expresses
ovalbumin (γ-MHV-68/OVA). This virus induces senescent
Blimp-1+ cells that can be distinguished from nonsenescent
Blimp-1− antigen-experienced cells by their expression of
KLRG1 (SI Appendix, Fig. S4C) (33, 34). OT-I cells, which had
been transduced with a control vector or retrovirus expressing
Yap 5SA, were adoptively transferred into mice that were then
infected with γ-MHV-68/OVA. Terminal differentiation of the
transferred CD8+ T cells during the peak of the primary re-
sponse at day 11 was suppressed by Yap 5SA, which was in-
dicated by the diminished expression of KLRG1 (Fig. 6E) and
the enhanced expression of CD127 (SI Appendix, Fig. S4D)
without a change in the magnitude of their clonal expansion (SI
Appendix, Fig. S4E).
Because the ligation of CTLA-4 triggers the Hippo pathway,
CTLA-4−/− T cells should resemble WT T cells expressing Yap
5SA in their response to stimuli that induce Blimp-1. Indeed,
activation of the puriﬁed, naïve CTLA-4−/− OT-I cell with anti-
gen and IL-2 was associated with diminished expression of
Blimp-1 relative to the response of WT OT-I cells (Fig. 6D).
Moreover, these cells, after adoptive transfer to WT mice, also
had diminished expression of KLRG1 (Fig. 6F) and enhanced
Fig. 4. Plasma membrane expression of CTLA-4 requires contact between activated CD8+ T cells. (A) Bar graph showing the mRNA levels of CTLA-4 relative to
the levels for CD3ε in naïve OT-I cells and OT-I cells stimulated for 24 h with 0.1 nM SIINFEKL peptide alone (TCR) or together with IL-2 (TCR + IL-2). Data
presented are the mean ± SEM. (B) Immunoblots showing CTLA-4 and actin protein in lysates of naïve OT-I cells and OT-I cells stimulated for 24 h with 0.1 nM
SIINFEKL peptide alone (TCR) or together with IL-2 (TCR + IL-2). (C) FACS analysis of CTLA-4 expression by TCR- and IL-2–stimulated Thy1.2+ OT-I cells that had
been cocultured for 30 h alone or with increasing numbers of resting polyclonal Thy1.1+ CD8+ T cells. The numbers represent the proportion of intact and
detergent-permeabilized Thy1.2+ cells, respectively, showing speciﬁc staining with anti–CTLA-4. (D) FACS analysis of CTLA-4 expression by TCR and IL-2–
stimulated Thy1.2+ OT-I cells that had been cultured in the top compartment of a transwell chamber in which the bottom compartment contained activated
Thy1.2+ OT-I cells cocultured with 100-fold excess polyclonal CD8+ T cells. The numbers represent the proportion of intact, nonpermeabilized Thy1.2+ cells
staining with anti–CTLA-4. *P < 0.05; ***P < 0.001.
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expression of CD127 (SI Appendix, Fig. S4F) at the peak of the
primary response to γ-MHV68/OVA infection without a change
in the magnitude of their clonal expansion (SI Appendix, Fig.
S4G). Thus, maintaining the expression of endogenous Yap in
the activated CD8+ T cell by deletion of the Hippo pathway
receptor, CTLA-4, has the same phenotypic consequences as
introduction of the Hippo pathway-resistant Yap 5SA. The
present ﬁnding that the Hippo pathway links the expression of
a gene that mediates differentiation, Blimp-1, to the population
density of activated CD8+ T cells is reminiscent of quorum
sensing in bacteria and allows us to propose the following model.
In the early phase of the immune response, replication will drive
clonal expansion, because the low frequency of antigen-speciﬁc
CD8+ T cells makes contact between them improbable and
CTLA-4 is not surface-expressed. Only when replication has
increased their numbers will contact between activated cells and
triggering of the Hippo pathway be likely to occur, which then
will create a steady state wherein the rates of differentiation and
replication are balanced.
Discussion
The present study ﬁnds that the Hippo pathway provides the
activated CD8+ T cell with a means for regulating Blimp-1
expression that is independent of other cell types. Because
triggering of the Hippo pathway is mediated by contact be-
tween activated CD8+ T cells, this mechanism for controlling
Blimp-1 expression would be linked to the frequency of acti-
vated CD8+ T cells within a larger population of nonactivated
T cells, which would be a measure of the magnitude of clonal
expansion in, for example, a lymph node. Thus, the Hippo
pathway has the requisite properties to allow replicating CD8+
T cells to select the appropriate time for Blimp-1 expression
and terminal differentiation.
The naïve CD8+ T cell differs from other cell types in which
the Hippo pathway has been studied in that Mst1 is the only
member of the core components of the pathway that is expressed
constitutively (Fig. 1A). The need of the naïve CD8+ T cell to
express Mst1 is consistent with other ﬁndings that Mst1 has bi-
ological activities independent of the Hippo pathway (35).
WW45, Lats1, Mob1, and Yap were all posttranscriptionally
regulated, requiring both antigen and IL-2 for their expression
(Figs. 1 and 2), indicating that the growth factors of clonal ex-
pansion rapidly establish the core Hippo pathway in the CD8+ T
cell. The essential role for IL-2 in the protein translation of the
core Hippo components and the CTLA-4/CD80 receptor–ligand
pair (Figs. 3 and 4) indicates that IL-2, by inducing both Yap and
the serine kinases involved in its degradation and nuclear ex-
clusion, can have the opposing functions of suppressing or per-
mitting Blimp-1 expression. This dual role for IL-2 in the Hippo
pathway is reminiscent of its capacity to promote the de-
velopment of both memory and terminally differentiated CD8+
T cells (20–24).
The Hippo pathway was activated in puriﬁed CD8+ T cells
that were cultured in the presence of antigen and IL-2, which was
indicated by the loss of Yap protein secondary to its phosphor-
ylation at serine-382 (Fig. 2D), indicating that no other cell types
Fig. 5. Activation of the Hippo pathway by CTLA-4 in vitro and in vivo. (A) Immunoblot analysis of lysates from activated OT-I cells cultured in the presence of
antibodies to CD80 and CD86 and incubated for 1 h with beads bearing isotype control antibody or antibody to CTLA-4. Blots were developed with antibodies
speciﬁc for phosphothreonine-183 of Mst1 and phosphoserine-909 of Lats1. Staining of actin is shown as a loading control. (B) Immunoblot analysis with
antiphosphoserine-112 of Yap of lysates from activated OT-I cells expressing Yap S382A-HA that had been cultured in the presence of blocking antibodies to
CD80 and CD86 and incubated for 1 h with beads bearing isotype control antibody or antibody to CTLA-4. HA staining is shown as a loading control. (C)
Immunoblot analysis of WT Yap in cell lysates from OT-I cells activated in the presence of antibodies to CD80 and CD86 and incubated for 3 h with beads
bearing various ratios of isotype control antibody and antibody to CTLA-4. Staining of actin is shown as a loading control. (D) Analysis by confocal microscopy
of anti-Yap–stained OT-I cells that had been activated in the presence of blocking antibodies to CD80 and CD86 and incubated for 3 h with beads bearing
isotype control antibody or antibody to CTLA-4 (green, anti-Yap; blue, DAPI). (Scale bars: 50 μm.) (E) Immunoblot analysis of Yap protein in lysates from CTLA-
4−/− OT-I cells and WT OT-I cells that had been activated with SIINFEKL peptide and IL-2 for 24 h. (F) Analysis by confocal microscopy of Yap protein in CD8+
and CD4+ cells from the lymph nodes of CTLA-4−/− and CTLA-4−/+ 16- to 20-d-old mice. (Scale bars: 10 μm.)
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were required for this process. The appearance of Yap protein in
activated CD8+ T cells after the addition of nonactivated CD8+
T cells (Fig. 2C) suggested that contact between the activated
CD8+ T cells triggers the Hippo pathway.
Two independent studies reported that activation of lympho-
cyte function-associated antigen 1 (LFA-1) in lymphocytes in-
volved Mst1 (36) and CTLA-4 (37), respectively, which raised
the possibility that a Hippo core component and this lymphocyte
receptor were in a common pathway. A triggering role for
CTLA-4 was consistent with the up-regulation of CD80 by an-
tigen- and IL-2–stimulated CD8+ T cells (Fig. 3 A and B), which
induced Hippo pathway activation, and the absence of CD80 and
CD86 on resting CD8+ T cells, which did not have this function
(Fig. 2C). More importantly, blocking antibodies to CD80 and
CD86 suppressed Yap degradation in contacting activated CD8+
T cells (Fig. 3 C and D), which identiﬁed CD28 and CTLA-4 as
the only two candidates for the Hippo pathway receptor. CTLA-
4 was formally shown to be a Hippo pathway receptor by the
ability of immobilized anti–CTLA-4, an unambiguous ligand for
CTLA-4, to induce the phosphorylation of Mst1, Lats1, and Yap
(Fig. 5 A and B); the degradation of Yap (Fig. 5 C and D) by the
stability of Yap in activated CTLA-4−/− CD8+ T cells in vitro
(Fig. 5E) and in vivo (Fig. 5F); and the inability of agonistic anti-
CD28 to induce degradation of Yap (SI Appendix, Fig. S1B).
Two interactions between activated CD8+ T cells, therefore,
may be required for Hippo pathway activation. The ﬁrst in-
teraction involves undeﬁned membrane components and leads to
CTLA-4 expression at the plasma membrane of the antigen- and
IL-2–stimulated cells (Fig. 4 C and D), which may indicate how,
during the early phase of clonal expansion when the low fre-
quency of activated CD8+ T cells would make contact between
them unlikely, the ligation of CD28 is favored over CTLA-4 by
CD80 and CD86 on antigen-presenting cells. The second in-
teraction involves CD80 and possibly, CD86 on one cell and
CTLA-4 on the other cell, which initiates the Hippo pathway
kinase cascade. Effects of T-cell–T-cell interactions involving
CD80 and CTLA-4 have been observed in vivo (38) and sug-
gested previously to induce anergy (39). Furthermore, these ac-
tivated T-cell–T-cell interactions have been directly visualized in
vivo and shown to occur through stable, multifocal synapse-like
structures (40) to which the microtubule-organizing complex
polarizes. Of interest in this regard is the observation that
CTLA-4 localizes to the microtubule-organizing complex (41).
Blocking the transcriptional consequences of Hippo pathway
activation by expressing Yap 5SA at physiological levels (SI
Appendix, Fig. S3) enhanced expression of Eomes and sup-
pressed expression of Blimp-1 (Fig. 6 A–C), indicating that the
Hippo pathway enables contact between activated CD8+ T cells
to regulate the expression of these two transcription factors that
are involved in terminal differentiation. Two prior studies ex-
amining the in vivo phenotype of Blimp-1−/− CD8+ T cells both
showed impaired KLRG1 and enhanced CD127 expression,
despite having conﬂicting conclusions regarding secondary mem-
ory responses (4, 5). The present ﬁnding that Yap 5SA or CTLA-
4 deﬁciency suppresses the development of the terminally differ-
entiated KLRG1+/CD127lo CD8+ T cell during a viral infection
(Fig. 6 E and F and SI Appendix, Fig. S4 D and F) is consistent
with the ability of Yap 5SA or CTLA-4 deﬁciency to suppress
Blimp-1 expression in vitro.
The relationship between the ﬁnding that CTLA-4 is the
triggering receptor of the Hippo pathway leading to Blimp-1
expression and the phenotypic characteristics of the CTLA-4−/−
mouse may be complex. For example, the CTLA-4−/− mouse has
massive lymphoproliferation (42, 43), and maintaining Yap ex-
pression in hepatocytes causes an apparently similar phenotype
of marked hepatomegaly (25). However, the Yap 5SA-expressing
CD8+ T cell and the CTLA-4−/− CD8+ T cell responding to
a viral infection showed mainly impaired markers of terminal
differentiation (Fig. 6 E and F and SI Appendix, Fig. S4 D and F)
and not excessive clonal expansion (SI Appendix, Fig. S4 E and
G). The marked lymphoproliferation of CTLA-4−/− mice, how-
ever, may reﬂect the effects of persistent stimulation of effector
cells by self-antigen caused by the loss of regulatory function by
CD4+ Foxp3+ T cells, whereas control of a viral infection would
Fig. 6. Preventing Hippo pathway activation in CD8+ T cells affects Blimp-1 expression and differentiation. (A) OT-I CD8+ T cells were transduced with the Yap
5SA-expressing retrovirus or the pMig vector control and analyzed for Eomes protein by staining of permeabilized cells with anti-Eomes relative to naïve,
unstimulated OT-I cells 16 h after restimulation with IL-2 and SIINFEKL peptide. Numbers represent the Eomes-speciﬁc mean ﬂuorescence intensity ± SEM. (B)
Prdm1gfp/+ CD8+ T cells that had been transduced with control pMig (black line) or the pMig vector-expressing Yap 5SA (red line) and WT CD8+ T cells
transduced with pMig (shaded) were restimulated for 48 h with anti-CD3ε and IL-2 and assessed for GFP ﬂuorescence. Numbers are the GFP-speciﬁc mean
ﬂuorescence intensities ± SEM. (C and D) OT-I cells transduced with a retrovirus expressing the Lats-resistant Yap 5SA or pMig control vector (C) and CTLA-4+/+
or CTLA-4−/− OT-I cells (D) were analyzed for Blimp-1 mRNA 48 h after restimulation with IL-2 and SIINFEKL peptide. The levels of Blimp-1 mRNA relative to the
levels of naïve unstimulated OT-I cells are shown. Data presented are the mean ± SEM. (E and F) Thy1.2+ OT-I cells that had been transduced with the Yap 5SA-
expressing retrovirus or control pMig (E), and Thy1.2+ CTLA-4−/− OT-I cells or CTLA-4+/+ OT-I cells (F) were adoptively transferred to Thy1.1+ C57BL/6 mice, and
2 d later, the mice were infected with γ-MHV-68/OVA. On days 8 and 11 postinfection, peripheral blood Thy1.2+ OT-I cells were assessed for expression of
KLRG1. Numbers represent the percentage KLRG1+ cells (means ± SEM). *P < 0.05.
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diminish the availability of antigen and terminate clonal expan-
sion. Furthermore, with regard to whether the primary role of
the Hippo pathway is to control proliferation or differentiation,
recent reports emphasize the latter function. Overexpression of
Yap in murine intestine or chick neural tubes results in loss of
differentiated cells (44, 45), and loss of WW45 leads to defective
terminal differentiation in skin, intestine, and lung epithelia (46).
Our results, moreover, are consistent with a previous study of
CTLA-4–deﬁcient CD8+ T cells in mixed bone marrow chimeric
mice, which reported no difference in clonal expansion between
WT and CTLA-4−/− CD8+ T cells (47, 48); unfortunately,
markers of terminal differentiation, such as KLRG1 and CD127,
were not evaluated. The relevance of the present studies to the
question of the function of CTLA-4 on the CD4+ Foxp3+ T cell
may be that, in its absence, there is impaired Hippo pathway-
mediated terminal differentiation and acquisition of regulatory
function, which has been shown for Blimp-1−/− regulatory T cells
(17). At the very least, the present ﬁnding of a cell-intrinsic
function for CTLA-4 in the activation of a conserved, ancient
developmental pathway, when coupled with the recent demon-
stration of its cell extrinsic function of transendocytosis of CD80
and CD86 (49), is additional evidence of the range of biological
activities of CTLA-4 that account for its central role in the
immune system.
Materials and Methods
The details of the mice strains used and their maintenance are contained in
S1 Materials and Methods. Similarly, the preparation of tissue samples and
cell culture, the antibodies used, the retroviral transduction, and the γ-MHV-
68/OVA infection are described there. Also included in this section are the
protocols fro the qRT-PCR, immunoblot, ﬂow cytometry and confocal assays.
ACKNOWLEDGMENTS. We thank F. Randow and E. Roberts for their helpful
discussions, F. Randow and A. Betz for their review of the manuscript, and
L. Walker for providing lymph nodes from CTLA-4 mutant mice. M.B.-W. was
supported by Sonderforschungsbereich Grant 854. This research was sup-
ported by the Wellcome Trust.
1. Khanna KM, McNamara JT, Lefrançois L (2007) In situ imaging of the endogenous CD8
T cell response to infection. Science 318:116–120.
2. Joshi NS, et al. (2007) Inﬂammation directs memory precursor and short-lived effector
CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity
27:281–295.
3. Banerjee A, et al. (2010) Cutting edge: The transcription factor eomesodermin
enables CD8+ T cells to compete for the memory cell niche. J Immunol 185:4988–4992.
4. Rutishauser RL, et al. (2009) Transcriptional repressor Blimp-1 promotes CD8(+) T cell
terminal differentiation and represses the acquisition of central memory T cell
properties. Immunity 31:296–308.
5. Kallies A, Xin A, Belz GT, Nutt SL (2009) Blimp-1 transcription factor is required for the
differentiation of effector CD8(+) T cells and memory responses. Immunity 31:
283–295.
6. Harrington LE, Janowski KM, Oliver JR, Zajac AJ, Weaver CT (2008) Memory CD4 T cells
emerge from effector T-cell progenitors. Nature 452:356–360.
7. Bannard O, Kraman M, Fearon DT (2009) Secondary replicative function of CD8+ T
cells that had developed an effector phenotype. Science 323:505–509.
8. Turner CA, Jr., Mack DH, Davis MM (1994) Blimp-1, a novel zinc ﬁnger-containing
protein that can drive the maturation of B lymphocytes into immunoglobulin-
secreting cells. Cell 77:297–306.
9. Kallies A, et al. (2011) A role for Blimp1 in the transcriptional network controlling
natural killer cell maturation. Blood 117:1869–1879.
10. Yeo CJ, Fearon DT (2011) T-bet-mediated differentiation of the activated CD8+ T cell.
Eur J Immunol 41:60–66.
11. Joshi NS, et al. (2011) Increased numbers of preexisting memory CD8 T cells and
decreased T-bet expression can restrain terminal differentiation of secondary effector
and memory CD8 T cells. J Immunol 187:4068–4076.
12. Pearce EL, et al. (2003) Control of effector CD8+ T cell function by the transcription
factor Eomesodermin. Science 302:1041–1043.
13. Rao RR, Li Q, Odunsi K, Shrikant PA (2010) The mTOR kinase determines effector
versus memory CD8+ T cell fate by regulating the expression of transcription factors
T-bet and Eomesodermin. Immunity 32:67–78.
14. Zhou X, et al. (2010) Differentiation and persistence of memory CD8(+) T cells depend
on T cell factor 1. Immunity 33:229–240.
15. Gong D, Malek TR (2007) Cytokine-dependent Blimp-1 expression in activated T cells
inhibits IL-2 production. J Immunol 178:242–252.
16. Pipkin ME, et al. (2010) Interleukin-2 and inﬂammation induce distinct transcriptional
programs that promote the differentiation of effector cytolytic T cells. Immunity 32:
79–90.
17. Cretney E, et al. (2011) The transcription factors Blimp-1 and IRF4 jointly control the
differentiation and function of effector regulatory T cells. Nat Immunol 12:304–311.
18. Kwon H, et al. (2009) Analysis of interleukin-21-induced Prdm1 gene regulation
reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31:
941–952.
19. Sun J, Dodd H, Moser EK, Sharma R, Braciale TJ (2011) CD4+ T cell help and innate-
derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat
Immunol 12:327–334.
20. Obar JJ, et al. (2010) CD4+ T cell regulation of CD25 expression controls development
of short-lived effector CD8+ T cells in primary and secondary responses. Proc Natl
Acad Sci USA 107:193–198.
21. Kalia V, et al. (2010) Prolonged interleukin-2Ralpha expression on virus-speciﬁc CD8+
T cells favors terminal-effector differentiation in vivo. Immunity 32:91–103.
22. Williams MA, Tyznik AJ, Bevan MJ (2006) Interleukin-2 signals during priming are
required for secondary expansion of CD8+ memory T cells. Nature 441:890–893.
23. BachmannMF, Wolint P, Walton S, Schwarz K, Oxenius A (2007) Differential role of IL-
2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J
Immunol 37:1502–1512.
24. Feau S, Arens R, Togher S, Schoenberger SP (2011) Autocrine IL-2 is required for
secondary population expansion of CD8(+) memory T cells. Nat Immunol 12:908–913.
25. Dong J, et al. (2007) Elucidation of a universal size-control mechanism in Drosophila
and mammals. Cell 130:1120–1133.
26. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL (2010) A coordinated phosphorylation
by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 24:72–85.
27. Schlegelmilch K, et al. (2011) Yap1 acts downstream of α-catenin to control epidermal
proliferation. Cell 144:782–795.
28. Magnúsdóttir E, et al. (2007) Epidermal terminal differentiation depends on B
lymphocyte-induced maturation protein-1. Proc Natl Acad Sci USA 104:14988–14993.
29. Nishioka N, et al. (2009) The Hippo signaling pathway components Lats and Yap
pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev
Cell 16:398–410.
30. Russ AP, et al. (2000) Eomesodermin is required for mouse trophoblast development
and mesoderm formation. Nature 404:95–99.
31. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP (2004) B7-1 and B7-2
selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21:
401–413.
32. Hegel JK, Knieke K, Kolar P, Reiner SL, Brunner-Weinzierl MC (2009) CD152 (CTLA-4)
regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Eur
J Immunol 39:883–893.
33. Voehringer D, et al. (2001) Viral infections induce abundant numbers of senescent
CD8 T cells. J Immunol 167:4838–4843.
34. Heffner M, Fearon DT (2007) Loss of T cell receptor-induced Bmi-1 in the KLRG1(+)
senescent CD8(+) T lymphocyte. Proc Natl Acad Sci USA 104:13414–13419.
35. Choi J, et al. (2009) Mst1-FoxO signaling protects Naïve T lymphocytes from cellular
oxidative stress in mice. PLoS One 4:e8011.
36. Katagiri K, ImamuraM, Kinashi T (2006) Spatiotemporal regulation of the kinase Mst1
by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol
7:919–928.
37. Schneider H, Valk E, da Rocha Dias S, Wei B, Rudd CE (2005) CTLA-4 up-regulation of
lymphocyte function-associated antigen 1 adhesion and clustering as an alternate
basis for coreceptor function. Proc Natl Acad Sci USA 102:12861–12866.
38. Taylor PA, et al. (2004) B7 expression on T cells down-regulates immune responses
through CTLA-4 ligation via T-T interactions [corrections]. J Immunol 172:34–39.
39. Chai JG, Vendetti S, Amofah E, Dyson J, Lechler R (2000) CD152 ligation by CD80 on T
cells is required for the induction of unresponsiveness by costimulation-deﬁcient
antigen presentation. J Immunol 165:3037–3042.
40. Sabatos CA, et al. (2008) A synaptic basis for paracrine interleukin-2 signaling during
homotypic T cell interaction. Immunity 29:238–248.
41. Egen JG, Allison JP (2002) Cytotoxic T lymphocyte antigen-4 accumulation in the
immunological synapse is regulated by TCR signal strength. Immunity 16:23–35.
42. Tivol EA, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal
multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Immunity 3:541–547.
43. Waterhouse P, et al. (1995) Lymphoproliferative disorders with early lethality in mice
deﬁcient in Ctla-4. Science 270:985–988.
44. Camargo FD, et al. (2007) YAP1 increases organ size and expands undifferentiated
progenitor cells. Curr Biol 17:2054–2060.
45. Cao X, Pfaff SL, Gage FH (2008) YAP regulates neural progenitor cell number via the
TEA domain transcription factor. Genes Dev 22:3320–3334.
46. Lee JH, et al. (2008) A crucial role of WW45 in developing epithelial tissues in the
mouse. EMBO J 27:1231–1242.
47. Bachmann MF, et al. (2001) Normal pathogen-speciﬁc immune responses mounted by
CTLA-4-deﬁcient T cells: A paradigm reconsidered. Eur J Immunol 31:450–458.
48. Bachmann MF, et al. (1998) Normal responsiveness of CTLA-4-deﬁcient anti-viral
cytotoxic T cells. J Immunol 160:95–100.
49. Qureshi OS, et al. (2011) Trans-endocytosis of CD80 and CD86: A molecular basis for
the cell-extrinsic function of CTLA-4. Science 332:600–603.
Thaventhiran et al. PNAS | Published online June 27, 2012 | E2229
IM
M
U
N
O
LO
G
Y
PN
A
S
PL
U
S
